New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
16:53 EDTQUREuniQure acquires InoCard in cash, stock
uniQure announced the acquisition of InoCard GmbH, an innovative, early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease. InoCard founders Patrick Most and Hugo Katus will join uniQure as managing director of uniQure in Germany and chairman of the scientific advisory board, for cardiovascular diseases, respectively. Under the terms of the agreement, InoCard shareholders will receive an upfront payment of 3M, 1.5M in cash and 1.5M in uniQure stock, and certain success-based milestones and royalties.
News For QURE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 14, 2015
08:38 EDTQUREuniQure and Treeway to develop Amyotrophic Lateral Sclerosis therapy
uniQure and Treeway B.V., founded by entrepreneurs Bernard Muller and Robbert Jan Stuit, both diagnosed with Amyotrophic Lateral Sclerosis, have announced a collaboration with to develop a gene therapy treatment for ALS. uniQure has granted Treeway an exclusive license in this field to uniQure's relevant AAV5 viral vector and GDNF intellectual property. Treeway is responsible for the preclinical and clinical development of the ALS gene therapy treatment. uniQure will provide Treeway with its manufacturing capabilities and will further collaborate with Treeway on ALS gene therapy development. Treeway and uniQure will jointly commercialize any resulting ALS gene therapy with defined geographical rights for commercialization assigned to each company. Financial details of the agreement have not been disclosed.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use